Kintara Therapeutics, Inc.

NasdaqCM:KTRA Stock Report

Market Cap: US$12.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Kintara Therapeutics Past Earnings Performance

Past criteria checks 0/6

Kintara Therapeutics has been growing earnings at an average annual rate of 2.4%, while the Biotechs industry saw earnings growing at 19.7% annually.

Key information

2.45%

Earnings growth rate

91.04%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-221.45%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Oct 19

Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial

Kintara Therapeutics (NASDAQ:KTRA) said it paused its REM-001 program in cutaneous metastatic breast cancer (CMBC) to save cash. The money will be used to fund an ongoing international registrational study of VAL-083 to treat a type of brain cancer called glioblastoma (GBM), the company said in a statement on Wednesday. Kintara President and CEO Robert Hoffman expects results from the GBM AGILE study of VAL-083 at the end of 2023. By pausing the REM-001 program, Kintara expects to save ~$3M through 2023. "We will continue to explore ways to restart REM-001, including use of grants from applications currently under review to support the funding of the planned 15-patient CMBC study. Although this was a difficult decision, we believe saving approximately $3.0 million through calendar year 2023 is prudent given the current capital market conditions," said Hoffman. KTRA +65.73% to $0.17 premarket Oct. 19
Seeking Alpha • Sep 27

Kintara Therapeutics GAAP EPS of -$0.52

Kintara Therapeutics press release (NASDAQ:KTRA): FY GAAP EPS of -$0.52. At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million.
Seeking Alpha • Aug 03

Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund

Kintara Therapeutics (NASDAQ:KTRA) stated Wednesday it has signed a direct equity purchase agreement for up to $20M investment with a Chicago-based institutional investor- Lincoln Park Capital Fund. Under the deal, Kintara will have the right, but not the obligation, to sell to LPC up to $20M of its shares over the period of 3-year agreement term. The company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation. KTRA shares jump 64% in pre-market, Wednesday.  Kintara said it intends to use net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.
Analysis Article • Apr 12

Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Revenue & Expenses Breakdown

How Kintara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:KTRA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-963
31 Mar 240-1055
31 Dec 230-1156
30 Sep 230-1358
30 Jun 230-1559
31 Mar 230-17611
31 Dec 220-19613
30 Sep 220-22715
30 Jun 220-25815
31 Mar 220-26915
31 Dec 210-281016
30 Sep 210-271014
30 Jun 210-421012
31 Mar 210-3999
31 Dec 200-3476
30 Sep 200-3054
30 Jun 200-954
31 Mar 200-853
31 Dec 190-853
30 Sep 190-853
30 Jun 190-854
31 Mar 190-844
31 Dec 180-945
30 Sep 180-1146
30 Jun 180-1147
31 Mar 180-1248
31 Dec 170-1137
30 Sep 170-936
30 Jun 170-935
31 Mar 170-1044
31 Dec 160-944
30 Sep 160-1043
30 Jun 160-933
31 Mar 160-633
31 Dec 150-623
30 Sep 150-422
30 Jun 150-423
31 Mar 150-122
31 Dec 140-232
30 Sep 140-232
30 Jun 140632
31 Mar 140-442

Quality Earnings: KTRA is currently unprofitable.

Growing Profit Margin: KTRA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KTRA is unprofitable, but has reduced losses over the past 5 years at a rate of 2.4% per year.

Accelerating Growth: Unable to compare KTRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KTRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).

Return on Equity

High ROE: KTRA has a negative Return on Equity (-221.45%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/17 16:02
End of Day Share Price 2024/10/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kintara Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group